LOCUS       sequence-55152-e         848 bp    DNA     linear   UNA 15-DEC-2025
DEFINITION  natural linear DNA
ACCESSION   .
VERSION     .
KEYWORDS    .
SOURCE      natural DNA sequence
  ORGANISM  unspecified
REFERENCE   1  (bases 1 to 848)
  AUTHORS   Sedgwick GG, Hayward DG, Di Fiore B, Pardo M, Yu L, Pines J, Nilsson
            J
  TITLE     Mechanisms controlling the temporal degradation of Nek2A and Kif18A 
            by the APC/C-Cdc20 complex.
  JOURNAL   EMBO J. 2013 Jan 23;32(2):303-14. doi: 10.1038/emboj.2012.335. Epub 
            2013 Jan 4.
  PUBMED    23288039
REFERENCE   2  (bases 1 to 848)
  AUTHORS   .
  TITLE     Direct Submission
  JOURNAL   Exported Dec 15, 2025 from SnapGene Server 8.0.1
            https://www.snapgene.com
COMMENT     SGRef: number: 1; type: "Journal Article"; doi: 
            "10.1038/emboj.2012.335"; journalName: "EMBO J"; date: "2013-01-23- 
            23"; volume: "32"; issue: "2"; pages: "303-14"
COMMENT     Sequence Label: pcDNA5/FRT/TO-Venus-Flag (865)
FEATURES             Location/Qualifiers
     source          1..848
                     /mol_type="genomic DNA"
                     /organism="unspecified"
     primer_bind     complement(149..173)
                     /label=LNCX
                     /note="Human CMV promoter, forward primer"
     protein_bind    183..201
                     /gene="tetO"
                     /label=tet operator
                     /bound_moiety="tetracycline repressor TetR"
                     /note="bacterial operator O2 for the tetR and tetA genes"
     protein_bind    204..222
                     /gene="tetO"
                     /label=tet operator
                     /bound_moiety="tetracycline repressor TetR"
                     /note="bacterial operator O2 for the tetR and tetA genes"
     promoter        complement(224..427)
                     /label=CMV promoter
                     /note="human cytomegalovirus (CMV) immediate early 
                     promoter"
     primer_bind     complement(253..273)
                     /label=CMV-F
                     /note="Human CMV immediate early promoter, forward primer"
     enhancer        428..807
                     /label=CMV enhancer
                     /note="human cytomegalovirus immediate early enhancer"
ORIGIN
        1 gctcctcgcc cttgctcacc atccaccaca ctggactagt ggatccgagc tcggtaccaa
       61 gcttaagttt aaacgctaga gtccggaggc tggatcggtc ccggtgtctt ctatggaggt
      121 caaaacagcg tggatggcgt ctccaggcga tctgacggtt cactaaacga gctcgtcgac
      181 gatctctatc actgataggg agatctctat cactgatagg gagagctctg cttatataga
      241 cctcccaccg tacacgccta ccgcccattt gcgtcaatgg ggcggagttg ttacgacatt
      301 ttggaaagtc ccgttgattt tggtgccaaa acaaactccc attgacgtca atggggtgga
      361 gacttggaaa tccccgtgag tcaaaccgct atccacgccc attgatgtac tgccaaaacc
      421 gcatcaccat ggtaatagcg atgactaata cgtagatgta ctgccaagta ggaaagtccc
      481 ataaggtcat gtactgggca taatgccagg cgggccattt accgtcattg acgtcaatag
      541 ggggcgtact tggcatatga tacacttgat gtactgccaa gtgggcagtt taccgtaaat
      601 actccaccca ttgacgtcaa tggaaagtcc ctattggcgt tactatggga acatacgtca
      661 ttattgacgt caatgggcgg gggtcgttgg gcggtcagcc aggcgggcca tttaccgtaa
      721 gttatgtaac gcggaactcc atatatgggc tatgaactaa tgaccccgta attgattact
      781 attaataact agtcaataat caatgtcaac gcgtatatct ggcccgtaca tcgcgaagca
      841 gcgcaaaa
//
